Laktulose MIP Pharma 650 mg/ ml Norge - norsk - Statens legemiddelverk

laktulose mip pharma 650 mg/ ml

mip pharma gmbh - laktulose - mikstur, oppløsning - 650 mg/ ml

Protaminsulfat LEO Pharma 1400 anti-heparin IE/ ml Norge - norsk - Statens legemiddelverk

protaminsulfat leo pharma 1400 anti-heparin ie/ ml

leo pharma (2) - protaminsulfat - injeksjons-/infusjonsvæske, oppløsning - 1400 anti-heparin ie/ ml

Nyxoid Den europeiske union - norsk - EMA (European Medicines Agency)

nyxoid

mundipharma corporation (ireland) limited - nalokson hydrochloride dihydrat - opioid-relaterte lidelser - alle andre terapeutiske produkter - nyxoid er beregnet til umiddelbar administrasjon som akuttapi for kjent eller mistenkt opioid overdose som manifestert av respiratorisk og / eller sentralnervesystemet depresjon i både ikke-medisinske og helsetjenester. nyxoid is indicated in adults and adolescents aged 14 years and over. nyxoid is not a substitute for emergency medical care.

Methenamine hippurate EQL Pharma 1 g Norge - norsk - Statens legemiddelverk

methenamine hippurate eql pharma 1 g

eql pharma ab - metenaminhippurat - tablett - 1 g

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Den europeiske union - norsk - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Colecalciferol EQL Pharma 2000 IE Norge - norsk - Statens legemiddelverk

colecalciferol eql pharma 2000 ie

eql pharma ab - kolekalsiferol - tablett - 2000 ie

Deflazacort Vital Pharma Nordic 6 mg Norge - norsk - Statens legemiddelverk

deflazacort vital pharma nordic 6 mg

vital pharma nordic aps - deflazakort - tablett - 6 mg

Daptomycin Accordpharma 500 mg Norge - norsk - Statens legemiddelverk

daptomycin accordpharma 500 mg

accord healthcare b.v. - daptomycin - pulver til injeksjons-/infusjonsvæske, oppløsning - 500 mg

Midazolam Accordpharma 1 mg/ ml Norge - norsk - Statens legemiddelverk

midazolam accordpharma 1 mg/ ml

accord healthcare b.v. - midazolamhydroklorid - injeksjons-/infusjonsvæske, oppløsning i ferdigfylt sprøyte - 1 mg/ ml

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Den europeiske union - norsk - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevasjon akutte myocardial infarction, i kombinasjon med asa i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for ytterligere informasjon, vennligst referer til seksjon 5.